This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Esomeprazole Strontium Delayed-Release

Hanmi Pharmaceutical Co., Ltd.

Drug Names(s): esomeprazole strontium delayed-release

Description: Esomeprazole Strontium is a proton pump inhibitor that suppresses gastric acid secretion by specific inhibition of H+/K+-ATPase in the gastric parietal cell. By acting specifically on the proton pump, esomeprazole blocks the final step in acid production, thus reducing gastric acidity.

Esomeprazole Strontium is a delayed-release, bioequivalent formulation of Nexium.

Deal Structure: Hanmi and Amneal
In January 2013, Amneal announced that it has entered into a license and distribution agreement with Hanmi to acquire exclusive distribution rights to Hanmi's new drug application (NDA) for esomeprazole strontium delayed-release capsules.

Partners: Amneal Pharmaceuticals, LLC


Esomeprazole Strontium Delayed-Release News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug